Sixty three patients aged 27-66 years (median 52) were allografted from HLA-matched sibling (n ¼ 47), 10 of 10 allele-matched unrelated (n ¼ 19), or one-antigen/allelemismatched (n ¼ 7) donors aged 24-69 years (median 46) after a conditioning regimen comprising 100 mg/m 2 melphalan. Cyclophosphamide (50 mg/kg) was also administered to patients who had not been autografted previously. Cyclosporine or tacrolimus, and mycophenolate mofetil were administered to prevent graft-versus-host disease (GVHD). The 2-year cumulative incidences of relapse and TRM were 55 and 24% respectively, and 2-year probabilities of overall survival (OS) and diseasefree survival (DFS) were 36 and 21%, respectively. Poor performance status, donor age 445 years and elevated lactate dehydrogenase (LDH) increased the risk of treatment-related mortality (TRM), refractory disease and donor age 445 years increased the risk of relapse, and OS and DFS were adversely influenced by refractory disease, poor performance status, increased LDH, and donor age 445 years. Our data suggest that younger donor age is associated with better outcome after submyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies due to lower TRM and relapse. This finding raises the question of whether a young 10-allele-matched unrelated donor is superior to an older matched sibling donor in patients where the clinical situation permits a choice between such donors.
Introduction
In addition to its utility in patients considered unsuitable for conventional-intensity (myeloablative) allogeneic hematopoietic stem cell transplantation (CI-HSCT), reducedintensity allogeneic HSCT (RI-HSCT) is increasingly being used as an alternative in patients who could otherwise be eligible for CI-HSCT and in a tandem autograft-allograft setting. [1] [2] [3] [4] Older donor age has been shown to be associated with poorer outcome of CI-HSCT through a combination of higher treatment-related mortality (TRM) and relapse. [5] [6] [7] [8] However, it is not known if donor age affects the outcome of RI-HSCT.
We studied the outcome of 63 adult patients undergoing RI-HSCT from adult donors to study the effect of pretransplant patient-, donor-and disease-related variables including donor age.
Patients and methods
Records of 63 consecutive patients undergoing RI-HSCT using a uniform, melphalan-based conditioning regimen were reviewed after approval from the institutional review board. The treatment period comprised March 2001 to May 2004.
All patients had hematologic malignancies requiring allogeneic HSCT, and 58 were felt to be unsuitable for CI-HSCT because of prior autograft, advanced age (X50 years), poor performance status (41), compromised organ function, concomitant active medical conditions or a combination of these features. There was no obvious reason to choose RI-HSCT in five others than a feeling that the underlying diseases were not aggressive enough to require CI-HSCT. Of the 40 sibling donors, 37 were matched at six of six HLA antigens tested (A, B, DR) using low-resolution DNA typing, and three were mismatched at a single antigen. Of the 23 donors identified through the National Marrow Donor Program, 19 were matched at 10 of 10 alleles tested (A, B, C, DRB1 DQB1) using high-resolution DNA typing, and four were mismatched at a single allele. Donors were aged 24-69 years (median 46). Table 1 shows patient characteristics for the entire group of patients as well as a comparison between those with younger donors (p45 years) and those with older donors (445 years). Patients with older donors were significantly older themselves, and tended to have myeloma more frequently and lymphoma less frequently. Three of 23 unrelated donors were 445 years of age compared with 30 of 40 sibling donors (Po0.0001). Two patients with relapsed disease were allografted without having received salvage therapy and were considered non-refractory for the purpose of analysis. All other patients had received primary or salvage chemotherapy prior to HSCT, and could be clearly classified as having refractory or sensitive (nonrefractory) disease based upon response (non-refractory) or stability/progression (refractory).
Conditioning regimen
Patients who had relapsed after a previous autograft received 100 mg/m 2 melphalan followed 24 h later by donor stem cell infusion. Those not autografted previously received 50 mg/kg cyclophosphamide with mesna 24 h before melphalan. The drugs were dosed based on the actual body weight if it was less than the ideal weight, and on adjusted body weight (ideal þ 25% of the difference between actual and ideal) if the actual weight was greater than the ideal.
Stem cell mobilization and graft characteristics All donors underwent leukapheresis after stimulation with granulocyte colony-stimulating factor (G-CSF), and bloodderived stem cells were used exclusively for transplantation. The CD34 þ cell dose measurement was based upon the patient's ideal body weight. 9, 10 Based upon our previous experience in myeloablative HSCT, 11 3 Â 10 6 CD34 þ cells/ kg was considered a minimum acceptable dose from sibling donors. Siblings underwent leukapheresis on more than one occasion if needed to meet the minimum cell dose requirement. While the same cell number was requested of the unrelated donors, the final collection was determined by the harvest center, and was below the minimum acceptable in four cases. All unrelated donor stem cells were used fresh, and all sibling donor stem cells had been collected and cryopreserved before starting the conditioning regimen.
Graft-versus-host disease prophylaxis
Patients allografted from HLA-identical sibling donors received cyclosporine from day À1 at the dose of 3 mg/kg as a continuous intravenous infusion. This was switched to oral as soon as engraftment had occurred, and oral intake was consistent and predictable. The target cyclosporine levels (ng/ml) during the first 6-7 weeks and during periods of significant graft-versus-host disease (GVHD) were 250-350 (steady-state levels on intravenous therapy using highperformance liquid chromatography), 200-300 (trough levels on oral therapy using high-performance liquid chromatography), 475-675 (steady-state levels on intravenous therapy using TDX), or 375-575 (trough levels on oral therapy using TDX). Patients allografted from mismatched sibling donors or unrelated donors (irrespective of HLA match grade) received tacrolimus from day À1 at the dose of 0.05 mg/kg as a continuous intravenous infusion. This was changed to oral as soon as engraftment had occurred and oral intake was adequate. The target tacrolimus level (ng/ml) was 10-15 (steady-state levels on intravenous therapy using TDX) or 8-12 (trough levels on oral therapy using TDX). The calcineurin inhibitor was tapered from the seventh week post-transplant onwards with a view to discontinuing it completely between 100 and 150 days post-transplant in the absence of clinically significant GVHD requiring immunosuppressive therapy. All patients also received mycophenolate mofetil 1000 mg twice daily orally; from day 21 to 150 in recipients of matched sibling cells and from day 1 to 150 in the others. Donor age and outcome of allografts J Mehta et al GVHD was treated with corticosteroids in addition to the prophylactic agents, and salvage agents were added as needed, based upon response.
Supportive therapy
All patients received ciprofloxacin or levofloxacin from day 0 to day 60, valaciclovir 500 mg thrice daily from day À1 to 1 month beyond discontinuation of immunosuppression, itraconazole liquid 200 mg twice daily from day 0 to 1 month beyond discontinuation of immunosuppression, and monthly inhaled pentamidine or thrice-weekly trimethoprim-sulfamethoxazole from the time of engraftment to 1 month beyond discontinuation of immunosuppression. Itraconazole was switched to voriconazole if patients received corticosteroids for the treatment of GVHD. Owing to concerns about toxicity, no myeloid growth factors were used routinely post-transplant but G-CSF 300-480 mg was started daily if the total leukocyte count was p0.2 Â 10 9 /l on day 14.
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Statistical analysis Data were analyzed using SPSS for Windows (Release 10.0.5) as of 30 June 2005 (minimum follow-up of 41 year). The w 2 test was used to compare categoric variables and the Wilcoxon rank-sum test was used to compare continuous variables. The probabilities of disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method, and compared using the log-rank test. Cumulative incidence of TRM and relapse were estimated using each type of event as a competing risk for the other. Cumulative incidence of acute and chronic GVHD were estimated using TRM and relapse as competing events.
Two patients dying in CR of causes clearly unrelated to the transplant or the underlying disease (cardiac arrhythmia and exacerbation of pre-existing chronic obstructive pulmonary disease at 15.4 and 26.8 months, respectively) were censored at the time of death for computing OS and DFS, and were considered to have experienced competing events for calculating the cumulative incidence of TRM and relapse.
A number of pre-transplant variables were analyzed individually using the likelihood-ratio statistic of a proportional hazards regression model for their effect on OS. The factors found to be statistically significant (Pp0.05) in univariate fashion were entered into a step-wise Cox model to determine their contribution to TRM, relapse, DFS, and OS. These were patient age (o60 years vs X60 years), performance status (0 vs 1 vs X2), chemosensitivity (refractory vs non-refractory), donor (sibling vs unrelated), HLA (match vs mismatch), donor age (p45 years vs 445 years), 10 8 /kg CD3 þ cells infused (o3 vs X3), lactate dehydrogenase (LDH) (normal vs increased), platelet count (o100 vs X100 Â 10 9 /l), albumin (p3 vs 43 g/dl) and hemoglobin (o9 vs X9 g/dl). The factors not found to be significant in univariate analysis (and therefore not entered into the Cox model) were diagnosis, patient sex, race, donor sex, CD34 þ cell dose, prior autograft, glomerular filtration rate, blood group and cytomegalovirus serostatus.
The patient and donor age cutoff values chosen were based upon analyses of the effect of various cut-off values on OS -and the values showing the most significant disparity in outcome were chosen.
Results

Engraftment and GVHD
Prompt neutrophil recovery was seen in 62 patients; one patient died of malignant hyperthermia and multi-organ failure on day 12 before recovery of counts. The time to neutrophil (median 14 days) and platelet (median 17 days) recovery was comparable for patients with younger and older donors. The cumulative incidence of any grade of acute GVHD at 100 days was 57% (95% CI: 46-71%), and that of grades III-IV acute GVHD was 34% (95% CI: 22-50%). The cumulative incidence of chronic GVHD at 1 and 2 years was 22% (95% CI: 14-35%) and 25% (95% CI: 17-39%).
TRM, relapse and survival
Sixteen patients died of transplant-related causes at 0.4 to 30.9 months (median 3.7). The causes of death were multiorgan toxicity/failure (n ¼ 7), GVHD (n ¼ 6), renal failure (n ¼ 1), aspiration pneumonia (n ¼ 1) and mucormycosis (n ¼ 1). These were evenly distributed between patients with younger and older donors. Three of the seven patients dying from multi-organ failure had a PS of two or three, one had significantly abnormal renal function, and one had neurological deficits related to whole-brain radiation. All four patients receiving o3 Â 10 6 CD34 þ cells/kg engrafted, but eventually died of transplant-related causes (compared to 12 of 59 receiving an adequate CD34 þ cell dose; P ¼ 0.003).
Thirty-five patients were found to have recurrent or persistent disease at 0.5 to 30.1 months (median 3.7). Treatment for relapse was variable and comprised withdrawal of immunosuppression, donor cell infusions, and salvage chemotherapy in varying combinations. Eight relapsed patients were alive in CR 12.2 to 29.9 months after relapse (median 24.6), whereas 27 died of relapsed disease or consequences of subsequent therapy. Overall, 20 patients were alive at 13-52 months (median 29).
The 2-year cumulative incidences of relapse and TRM were 55% (95% CI: 44-69%) and 24% (95% CI: 15-37%) respectively, and 2-year probabilities of OS and DFS were 36% (95% CI: 24-48%) and 21% (95% CI: 11-31%) respectively.
Cox analysis
As shown in Table 2 , relapse was higher with refractory disease and donor age 445, TRM was higher with poorer PS, donor age 445 and increased LDH, and OS and DFS were lower with poorer PS, refractory disease, donor age 445, and increased LDH. Figures 1 and 2 depict the impact of donor age on DFS and OS in curves that have been adjusted for other variables. The survival curves shown have been derived from the final Cox model, and have been plotted at the means of the other covariates. Similarly, Figure 3 depicts Donor age and outcome of allografts J Mehta et al the combined effect of patient and donor age (donor and patient age categories were combined into a single category with four covariates) on OS in curves that have been adjusted for other variables.
The 100-day cumulative incidence of acute GVHD with younger donors was 60% compared to 55% with older donors. The 2-year cumulative incidence of chronic GVHD with younger donors was 37% compared to 15% with older donors. This difference was not statistically significant (RR 1.6, 95% CI 0.5-4.6, P ¼ 0.39). The development of chronic GVHD in patients alive at 100 days was associated with significantly better survival. However, this effect was not seen among those alive at 1 year, probably because of small numbers.
Discussion
Our data show that outcome of RI-HSCT is better in patients with younger donors. Previous work has shown superior outcome with younger donors in the setting of Figure 3 The combined effect of donor and patient age on overall survival; adjusted for all other variables (plotted at the means of the other covariates using the Cox model).
Donor age and outcome of allografts J Mehta et al CI-HSCT from HLA-identical sibling donors, 13 HLA-mismatched related donors 8 and from unrelated donors. 14, 15 However, to the best of our knowledge, this has not been shown with RI-HSCT previously.
The relevance of donor age may be greater with RI-HSCT than with CI-HSCT because, as the patient population treated is older than the CI-HSCT patient population, the related donor pool is much older too. In our group of patients, the related donors tended to be significantly older than unrelated donors ( Table 1) . As the donor type (unrelated vs sibling) did not affect outcome in the Cox model in this study, the first question that arises is whether the younger age of an unrelated donor compensates for the possible adverse impact of inherently higher immune incompatibility (which could increase graftversus-host reactivity and worsen outcome). The second, more intriguing, question that arises is whether a younger 10 of 10 allele-matched unrelated donor is superior to an older HLA-identical sibling donor.
The reasons for superior outcomes with younger donors are unclear. Advanced donor age has been shown to result in some loss of repopulating ability, 16 impaired homing ability, 17 an overall loss of function, 18 as well as accelerated telomere shortening. 19 Older T cells have also been shown to possess diminished effector activity. 20, 21 These shortcomings of older donor cells could explain the finding of better immune reconstitution among recipients of grafts from younger donors 22 and less donor-type chimerism in recipients of HSCT from older donors. 23 The functional impairment of donor stem cells and T cells could explain the increased TRM as well as the increased risk of relapse seen in our study. A number of studies have suggested a higher risk of GVHD with older donors. [24] [25] [26] However, in our study, donor age did not affect acute or chronic GVHD significantly -which could simply be a shortcoming of the small patient numbers.
The finding that neither older patient age nor limited HLA-mismatch affected outcome, while encouraging, should be interpreted with some caution because of the relatively small number of old patients and HLAmismatched donors. Excluding the seven HLA-mismatched transplants did not affect the analysis results (details not shown). As patients with older sibling donors tended to be older themselves, it is also possible that the superior outcome after HSCT from younger donors reflects some contribution of younger patient age too. As the underlying diagnosis did not affect outcome, it is unlikely that the higher prevalence of myeloma among patients with older donors and of lymphoma among patients with younger donors contributed to the differences in outcome. Finally, since unrelated donor cells were always used fresh and sibling cells were always cryopreserved, it is possible that some of the outcome difference may be attributable to this.
The limitations of this study are small patient numbers and relatively short follow-up -and therefore this observation requires confirmation in larger groups of patients. If it is confirmed, trying to identify a young unrelated donor may be worthwhile for a patient who only has an old sibling donor available -if the clinical situation permits the additional time such an approach would entail.
